{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1259332221", "close" : "1259344821", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
businesswire

SuperGen to Present at Merriman Curhan Ford Investor Summit on November 10, 2009


  • Press Release
  • Source: SuperGen, Inc.
  • On 6:00 am EST, Wednesday November 4, 2009

DUBLIN, Calif.--(BUSINESS WIRE)--SuperGen, Inc. (Nasdaq:SUPG - News), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that Mohammad Azab, M.D., Chief Medical Officer, will present at the Merriman Curhan Ford 6th Annual Investor Summit on Tuesday November 10, 2009 in New York.

Related Quotes

SymbolPriceChange
SUPG2.710.00
Chart for SuperGen, Inc.
{"s" : "supg","k" : "c10,l10,p20,t10","o" : "","j" : ""}

SuperGen's presentation will begin at 2 p.m. ET. A live webcast of the presentation will be available on the investor relations section of the Company's Web site at www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit http://www.supergen.com.

Contact:

SuperGen, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Business Development
tenns@supergen.com
Susanna Chau, 925-560-2845
Manager
Investor Relations
schau@supergen.com

Related Headlines

Related Blog Headlines

Top Stories

Related Message Boards

Sponsored Links

Copyright © 2009 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials by posting, archiving in a public web site or database, or redistribution in a computer network is strictly forbidden.